Attentional Bias in Body Dysmorphic Disorder (VAB)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by Massachusetts General Hospital.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Sabine Wilhelm, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01398904
First received: July 15, 2011
Last updated: August 31, 2012
Last verified: August 2012
  Purpose

Body Dysmorphic Disorder (BDD) participants will demonstrate greater attentional biases as compared to healthy control (HC) participants. Greater attention bias will be associated with greater distress. Greater attention bias will be associated with greater symptom severity.


Condition
Body Dysmorphic Disorders

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Attentional Bias in Body Dysmorphic Disorder

Further study details as provided by Massachusetts General Hospital:

Primary Outcome Measures:
  • Attention Pattern [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
    Gaze tracking via an Eyelink II eye tracker will determine perception of visual information.


Secondary Outcome Measures:
  • Subjective Units of Distress Scale (SUDS) [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
    Participants will provide a distress score based on the facial images observed.

  • Facial Attractiveness [ Time Frame: Day 2 ] [ Designated as safety issue: No ]
    Using a 9-point Likert scale, participants will rate the perceived most attractive and unattractive feature of their own and the control face.


Estimated Enrollment: 40
Study Start Date: March 2011
Groups/Cohorts
Body dysmorphic disorder (BDD) Participants
Participants must be 18 years or older with a primary diagnosis of body dysmorphic disorder (BDD), a BDD Yale-Brown Obsessive Compulsive Scale (BDDY-BOCS) score of >20, and a primary facial/head concern. Participants must have the ability to provide informed consent and understand study staff.
Healthy Controls
Males and females 18 years of age or older with ability to provide informed consent and understand study staff.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

The study will include 40 participants, consisting of 20 BDD participants and 20 matched healthy controls.

Criteria

Inclusion Criteria for BDD and healthy control participants:

  • males and females 18 years of age or older
  • sufficient fluency of English to understand study staff, procedures, and questionnaires
  • ability to provide informed consent

Inclusion for BDD participants only;

  • primary diagnosis of Diagnostic and Statistical Manual 4th Edition (DSM-IV-TR) BDD
  • BDD Yale-Brown Obsessive Compulsive Disorder score (Y-BOCS) of > 20
  • primary facial/head concern

Exclusion Criteria:

  • Major medical or neurological conditions
  • schizophrenia, schizoaffective disorder, or any other current lifetime DSM-IV psychotic disorder that is not attributable to delusional BDD
  • current suicidality
  • current homicidality

Exclusion criteria for healthy controls:

  • Any current Axis I psychiatric illness
  • history of BDD
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01398904

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
Investigators
Principal Investigator: Sabine Wilhelm, Ph. D. Massachusetts General Hospital
Study Director: Jennifer Greenberg, Psy. D. Massachusetts General Hospital
  More Information

Publications:

Responsible Party: Sabine Wilhelm, Director, OCD & Related Disorders Program, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01398904     History of Changes
Other Study ID Numbers: 2010P002912
Study First Received: July 15, 2011
Last Updated: August 31, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by Massachusetts General Hospital:
BDD

Additional relevant MeSH terms:
Disease
Body Dysmorphic Disorders
Pathologic Processes
Somatoform Disorders
Mental Disorders

ClinicalTrials.gov processed this record on September 18, 2014